Whether you are a stockholder, healthcare provider, a patient, or a parent of a child living with one of the diseases we are working to address, I hope that you find this website to be useful.

Since it was founded in 1997, BioMarin has successfully advanced three breakthrough products from research through FDA approval to patients--a remarkable accomplishment in the pharmaceutical industry. As a fully-integrated multinational commercial biotechnology company, BioMarin is leveraging its expertise in manufacturing, research, regulatory affairs and global commercial development, and is making significant strides in delivering first-to-market therapeutic treatments to patients with rare genetic diseases.

In 2007, we received FDA approval for our third product, Kuvan (sapropterin dihydrochloride) Tablets, the first drug therapy for the treatment of PKU. We also filed an IND for PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) and will soon initiate clinical trials. We are hopeful that the positive preclinical data showing sustained decreases in blood Phe levels in PKU mice will be replicated in humans. If proven safe and effective, PEG-PAL has tremendous potential and may have the ability to treat the entire spectrum of PKU patients who do not respond to, or wish to reduce blood Phe levels beyond what is possible with Kuvan.

Addressing new market opportunities
BioMarin is working to further diversify its product portfolio with various research and development programs. For example, BH4, the active ingredient in Kuvan, is currently being evaluated for a number of other indications such as sickle cell disease, pulmonary arterial hypertension and peripheral arterial disease. A variety of other promising preclinical programs are also being pursued with the goal of filing one IND per year to ensure continued growth.

The company's active global commercialization efforts are yielding hundreds of new MPS VI patients who can benefit from Naglazyme (galsulfase), BioMarin's first independently developed and commercialized enzyme replacement therapy. Worldwide demand for the product is increasing steadlity and is expected to grow in the coming year.

Looking Ahead in 2008
We are proud of our many achievements throughout the past year. The launch of Kuvan represents an important milestone for both BioMarin and the PKU community and while we are extremely pleased to have delivered this promising treatment to market, we also recognize the need to continually deliver additional value. To that end, we are investing in our internal pipeline and aggressively but prudently pursuing in-licensing and acquisition opportunities. We remain passionately dedicated to serving MPS I, MPS VI and PKU patients and we continue seeking new ways to enhance value to both patients and investors.

I would like to thank our patients, their families and physicians, and our corporate partners for helping to bring these important life-altering therapies to market. Thanks also to all of our employees and our Board of Directors for their hard work, dedication and passion for the patients we serve. Together, they have brought three novel products to market and continue to prove our expertise in providing high-value biopharmaceuticals to the patients who need them most. We appreciate your continued support and look forward to keeping you updated on our progress throughout the coming year.

Regards,



Jean-Jacques Bienaimé
Chief Executive Officer

April 2008

Back to Top